KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Payables (2016 - 2025)

Historic Payables for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $36.8 million.

  • Xenon Pharmaceuticals' Payables rose 3013.99% to $36.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year increase of 3013.99%. This contributed to the annual value of $34.2 million for FY2024, which is 3175.1% up from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Payables stood at $36.8 million, which was up 3013.99% from $31.6 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Payables high stood at $36.8 million for Q3 2025, and its period low was $7.6 million during Q1 2021.
  • For the 5-year period, Xenon Pharmaceuticals' Payables averaged around $21.7 million, with its median value being $22.2 million (2022).
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Payables tumbled by 623.45% in 2021, and later soared by 16681.28% in 2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Payables (Quarter) stood at $13.7 million in 2021, then soared by 61.95% to $22.2 million in 2022, then rose by 16.93% to $26.0 million in 2023, then skyrocketed by 31.75% to $34.2 million in 2024, then rose by 7.65% to $36.8 million in 2025.
  • Its Payables was $36.8 million in Q3 2025, compared to $31.6 million in Q2 2025 and $30.6 million in Q1 2025.